Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02810964 · ClinicalTrials.gov registry record · Phase 2
Sulforaphane to Reduce Symptoms of Schizophrenia
A Phase 2 study, sponsored by Sheppard Pratt Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02810964 is a Phase 2 study that has completed, run by Sheppard Pratt Health System. The registered enrollment target is 64 participants.
The verdict
NCT02810964, a Phase 2 study, has completed, sponsored by Sheppard Pratt Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
Interventions
- DRUG Sulforaphane Nutraceutical
- DRUG Identical-appearing Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2019-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02810964
The ClinicalTrials.gov registry entry for NCT02810964 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sheppard Pratt Health System, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sulforaphane Nutraceutical is the first listed.
NCT02810964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02810964 about?
NCT02810964 is a clinical study titled "Sulforaphane to Reduce Symptoms of Schizophrenia". The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
What is the current status of trial NCT02810964?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2017-02-22. Estimated completion is 2019-11-11.
What interventions are being tested in trial NCT02810964?
The interventions under investigation include: Sulforaphane Nutraceutical (DRUG), Identical-appearing Placebo (DRUG).
Who is sponsoring clinical trial NCT02810964?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.